Results: The majority of past-year nonalcohol DSM-5 SUDs had at least 1 other co-occurring past-year SUD, ranging from 56.8% (SE = 3.4) for past-year prescription opioid use disorder to 97.5% (SE = 2.7) for past-year hallucinogen use disorder. In contrast, only 15.0% (SE = 0.6) of past-year alcohol use disorders had a co-occurring past-year SUD. The odds of past-year multiple SUDs were greater among males, younger adults, African-Americans, and those with mood, personality, posttraumatic stress, or multiple psychiatric disorders.
Services Administration [SAMHSA], 2006 [SAMHSA], , 2012 [SAMHSA], , 2014a . More specifically, there has been a significant shift in the primary substances of abuse observed in those entering substance abuse treatment facilities. For instance, the percentage of substance abuse treatment facility admissions reporting alcohol as the primary substance of abuse has decreased from 57% in 1993 to 38% in 2013, whereas the percentage of substance abuse treatment facility admissions for cannabis, opioids, and stimulants as the primary substance increased from 22% in 1993 to 53% in 2013 (SAMHSA, 2006 (SAMHSA, , 2012 (SAMHSA, , 2014a ). In addition, there is growing evidence that adverse consequences appear to be more severe among polysubstance users relative to single-drug users (Abé et al., 2013; McCabe, Cranford, Morales, & Young, 2006; SAMHSA, 2014a) .
Although prior studies have found that DSM-IV and DSM-5 alcohol and cannabis use disorders often co-occur with other SUDs, most of these studies have aggregated less prevalent substance-specific SUDs such as cocaine, heroin, hallucinogens, inhalants, prescription opioids, sedatives or tranquilizers, stimulants, and/or other drugs (Compton et al., 2007; Grant & Pickering, 1996; Grant et al., 2016; Hasin et al., 2016; Stinson et al., 2005) . As a result, several studies have concluded that more in-depth investigations regarding the prevalence of multiple DSM-5 SUDs for these less prevalent substance-specific SUDs are warranted because the epidemiology of SUDs may differ across individual drug classes (Compton et al., 2007 (Compton et al., , 2013 Grant et al., 2016) . Although prior research has found that substance-specific SUDs are significantly associated with sociodemographic characteristics (e.g., sex, race, and age) and other psychiatric disorders (e.g., anxiety, eating, mood, and personality disorders), the associations with these and multiple SUDs have not been well examined (Grant, Goldstein, Saha, et al., 2015; Grant et al., 2004; Hasin et al., 2016; Kessler, Chiu, Demler, Merikangas, & Walters, 2005) .
The current lack of information regarding multiple DSM-5 SUDs for these less studied drug classes represents an important gap in our knowledge with direct relevance for enhanced screening, diagnosis, prevention, and treatment efforts. Therefore, the primary objective of this study was to examine the lifetime, prior-to-past-year, and past-year prevalence and correlates associated with multiple DSM-5 SUDs for 10 drug classes among U.S. adults based on a large nationally in the following group quarters: boarding or rooming houses, nontransient hotels, shelters, facilities for housing workers, college quarters, and group homes. In-person interviews were conducted, and the household, person, and overall response rates were 72%, 84%, and 60.1%, respectively. The NESARC-III sample design and weighting procedures, which adjust for potential biases introduced by nonresponse, have been described in more detail elsewhere (Grant, Chu, Sigman, et al., 2015; Grant, Goldstein, Saha, et al., 2015) . All procedures, including informed consent, received full human subjects review and institutional review board approval, and all relevant ethical safeguards have been met in relation to human subject protection.
| Measures
The measures in the AUDADIS-5 assessed several domains, including sociodemographic and background characteristics, DSM-5 SUDs, and other DSM-5 psychiatric disorders.
Sociodemographic and background characteristics were measured with several items, including sex, age, race or ethnicity, marital status, and geographical region based on the U.S. Census (northeast, south, north central, and west).
DSM-5 SUDs were assessed according to the criteria of the DSM-5 using the AUDADIS-5, including drug-specific diagnoses for 10 substances: alcohol, cannabis, cocaine, heroin, hallucinogens, inhalants, prescription opioids, sedatives or tranquilizers, stimulants, and other drugs (e.g., ecstasy and ketamine). Substance-specific diagnoses were made for three different timeframes: past year, prior to past year, and lifetime. Each DSM-5 SUD diagnosis required positive responses to two or more of the 11 criteria in the 12 months preceding the interview or previously for each drug-specific SUD. In this study, remission from SUDs was defined as not meeting criteria for SUD for a period of 12 months or longer among those who met full criteria for at least one SUD previously. The test-retest reliability and validity of each AUDADIS-5 DSM-5 SUD diagnosis have been examined in psychometric studies, with test-retest reliability ranging from fair to good (κ = .4-.7) and dimensional criterion scales (intraclass correlation coefficient = .5-.9, respectively) ranging from fair to excellent in a large general population sample (Grant, Goldstein, Smith, et al., 2015; Grant, Goldstein, Saha, et al., 2015; Grant et al., 2016; . More specifically, the procedural validity of the SUD diagnoses of the AUDADIS-5 was previously assessed using a clinician-administered semistructured interview Psychiatric Research Interview for Substance and Mental Disorders DSM-5 version (PRISM-5) in a large general population sample . The concordance between AUDADIS-5 and PRISM-5 diagnoses of lifetime, prior-to-past-year, and past-year DSM-5 binary diagnoses were good for all substances except for lifetime stimulants, prior-to-past-year hallucinogens and stimulants, and past-year opioids.
DSM-5 other psychiatric disorders were assessed using the AUDADIS-5, including lifetime anxiety disorders (i.e., agoraphobia, generalized anxiety disorder, panic, and social and specific phobias), mood disorders (i.e., bipolar, dysthymia, and major depressive disorder), eating disorders (i.e., anorexia nervosa, binge eating disorder, and bulimia nervosa), personality disorders (i.e., antisocial personality disorders, borderline, and schizotypal), and posttraumatic stress disorder. Consistent with DSM-5, all these diagnoses excluded substanceand medical-illness-induced disorders. Reliability and validity of the DSM-5-based AUDADIS-5 diagnoses of other psychiatric disorders have been established in numerous psychometric studies (Grant, Goldstein, Smith, et al., 2015; Hasin, Shmulewitz, et al., 2015) .
| Data analyses
All analyses in this study were design-based, using the survey weights provided in the NESARC-III data set to compute unbiased population estimates of the descriptive parameters of interest and the available codes describing the sampling strata and sampling clusters from the multistage stratified cluster sampling design to compute linearized variance estimates for the weighted estimates. Initial analyses focused on estimation of the lifetime, prior-to-past-year, and past-year prevalence of SUDs for specific drugs, multiple SUDs for specific drug classes, and ratios of the prevalence of multiple SUDs to the prevalence of individual SUDs for 10 specific drug classes. Ratios closer to 100% in this case would indicate that nearly all of the SUDs for a specific drug were accompanied by other SUDs.
Subsequent analyses focused on differences between subgroups defined by sociodemographic characteristics and prior psychiatric history in the prevalence of individual and multiple SUDs. These differences were tested using design-adjusted Rao-Scott chi-square tests.
The lifetime, prior-to-past-year, and past-year prevalence of multiple SUDs were compared for subgroups defined by sex (female or male), race or ethnicity (White, African American, Native American, Asian or Pacific Islander, or Hispanic), age (18-29, 30-44, 45-64, or 65 years and over) , and presence of other DSM-5 psychiatric conditions including anxiety, eating, mood, personality, and posttraumatic stress disorders (yes or no), in both bivariate analyses and multivariate logistic regression models. Importantly, given the overlap in some of the sociodemographic variables used to compute poststratification adjustments for the NESARC-III weights (Grant, Chu, Sigman, et al., 2015) and the variables used as covariates in our analytic models, we considered both weighted and unweighted estimates of the coefficients to assess possible inflation of the standard errors of the weighted estimates relative to changes in the actual estimates of the coefficients (Korn & Graubard, 1999) . Finally, males and females were compared in terms of the probability of having any past-year SUD, having only one past-year SUD, and having multiple past-year SUDs, as a function of prior-to-past-year SUD status. The svy: commands in the Stata software (Version 14.1) were used for all analyses.
3 | RESULTS
| Estimated population characteristics and prevalence of multiple DSM-5 SUDs
The NESARC-III sample consisted of 36,309 adults and, after the final survey weights were applied, represented a population that was 51.9% women, 66.2% White, 14.7% Hispanic, 11.8% African American, 5.7% Asian, and 1.6% Native American or other racial category.
As shown in Table 1 , the estimated prevalence ratios indicate that the majority of lifetime, prior-to-past-year, and past-year nonalcohol drug-specific DSM-5 SUDs (i.e., cannabis, cocaine, heroin, hallucinogens, inhalants, prescription opioids, sedatives or tranquilizers, stimulants, or other drugs) were accompanied by at least one other DSM-5 SUD. More specifically, the prevalence ratios for past-year nonalcohol drug use disorders ranged from 56.8% for prescription opioid use disorder to 97.5% for inhalant use disorder, indicating that the majority of past-year nonalcohol drug-specific SUDs were part of multiple past-year SUDs. The exception was alcohol use disorder, which regardless of the timeframe had significantly lower prevalence ratios of multiple SUDs.
| Prevalence and adjusted odds of multiple SUDs by sex, race, age, and other psychiatric disorders
The overall prevalence rates of multiple DSM-5 SUDs among U.S. adults were 7.8% (lifetime), 6.2% (prior to past year), and 2.3% (past year), whereas the prevalence rates of individual nonmultiple DSM-5 SUDs were 23.8% (lifetime), 19.2% (prior to past year), and 13.4% (past year).
As illustrated in Table 2 , there were significant differences in rates of multiple DSM-5 SUDs by sex, race, age, and other psychiatric disorders.
Multiple SUDs were generally more prevalent among males, young adults aged 18-29, African Americans, Native Americans, Whites, and those with a lifetime history of DSM-5 anxiety, mood, personality, eating, and posttraumatic stress disorders, in addition to those with multiple psychiatric disorders.
As shown in Table 3 , the adjusted odds of past-year multiple SUDs were greater among males, younger adults, African Americans, and those with mood, personality, or posttraumatic stress disorders, after adjusting for the other covariates. In addition, the adjusted odds of past-year multiple SUDs were over 3 times greater among adults with one lifetime psychiatric disorder (AOR = 3.40, 95% CI [2.68, 4.32], p < .001) compared to those with no lifetime psychiatric disorder. Furthermore, the adjusted odds of past-year multiple SUDs were nearly 9 times greater among those with multiple psychiatric disorders (AOR = 8.97, 95% CI [7.22, 11.14], p < .001; weighted estimates, not shown in Table 3 ), relative to those with no lifetime history of psychiatric disorders, after adjusting for the other covariates.
When comparing the weighted and unweighted estimates of the coefficients in our models, we found evidence of some increases in efficiency (i.e., lower standard errors and narrower confidence intervals) for the unweighted estimates, as might be expected given the covariates that were also used to develop weighting adjustments, but no changes were substantial enough to change the inferences that we would make using the weighted estimates (see Table 3 ). In general, the lack of substantial changes in the estimates of the adjusted odds ratios does suggest that using the weights to fit these models may be unnecessary, given the factors that were used for poststratification. This is also evidence that our model has been well specified (Heeringa, West, & Berglund, 2017, Chapter 7).
3.3 | Prevalence of past-year SUDs as a function of prior-to-past-year SUD status Table 4 shows that individuals with multiple prior-to-past-year SUDs are less likely to remit from SUDs than those with an individual (nonmultiple) prior-to-past-year DSM-5 SUD. The estimated past-year prevalence rate of any SUD among those with no prior-to-past-year DSM-5 SUDs was lowest at 8.2%. In contrast, the past-year prevalence rate of any SUD was highest among those with multiple prior-to-pastyear alcohol and other drug use disorders (49.9%), followed by those with only a prior-to-past-year nonalcohol drug use disorder (40.5%) and those with only a prior-to-past-year alcohol drug use disorder (32.9%). There were also sex differences in the past-year prevalence rates of any SUD among adults with no prior-to-past-year SUDs or only alcohol use disorders. However, once individuals had multiple prior-topast-year SUDs or prior-to-past-year nonalcohol other drug SUDs, the prevalence of any past-year SUDs was high in general, and male versus female differences in the past-year SUD prevalence rates were no longer present.
3.4 | Prevalence of substance-specific versus any SUDs as a function of prior SUD for 10 drug classes As illustrated in Table 5 , the past-year prevalence rates of any DSM-5 SUD among those with prior-to-past-year drug-specific DSM-5 drug use disorders ranged from 37.2% for prior-to-past-year DSM-5 alcohol use disorder to 53.5% for prior-to-past-year DSM-5 prescription opioid use disorder. There were no significant sex differences in the past-year prevalence rates of any SUD among adults with prior-to-past-year SUDs. Among individuals with a prior-to-past-year alcohol use disorder, other SUDs involving different substances were quite unlikely to develop in the past year (3.0%). However, among individuals with prior-to-past-year SUDs not related to alcohol, the development of The age-adjusted drug overdose death rate has more than doubled from 6.2 per 100,000 persons in 2000 to 14.7 per 100,000 in 2014, and many of these deaths involve polysubstance use (Rudd et al., 2016 ).
There has also been a significant shift nationally in the profile of individuals entering U.S. substance abuse treatment facilities (SAMHSA, 2006 (SAMHSA, , 2012 (SAMHSA, , 2014a , and previous evidence from national surveys suggests Multiple (2+) 21.5 (0.6)*** 17.8 (0.6)*** 6.6 (0.4)*** Note. All percentages weighted using AUDWEIGHT. Tests of association are based on design-adjusted Rao-Scott tests. Any lifetime psychiatric disorders refer to any history of lifetime anxiety, mood, eating, personality, or posttraumatic stress disorders. Anxiety disorders refer to agoraphobia, generalized anxiety disorder, panic, and social and specific phobias; mood disorders refer to bipolar, dysthymia, and major depressive disorders; personality disorders refer to antisocial, borderline, and schizotypal personality disorders; eating disorders refer to anorexia nervosa, binge-eating disorder, and bulimia nervosa. DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, fifth edition. Source: National Epidemiologic Survey on Alcohol and Related Conditions III. ***p < .001 (for Rao-Scott test of bivariate association). (Blanco, Secades-Villa, García-Rodríquez, et al., 2013; McCabe et al., 2008) . Taken together, the findings from the present study and the two prior studies provide evidence from three independent nationally representative samples over the past two decades that the majority of adults with drug-specific past-year prescription drug use disorders involving opioids, sedatives or tranquilizers, and stimulants also met criteria for another SUD ( For example, previous work found that the majority of adolescents and young adults who engage in nonmedical use of prescription drugs Note. Anxiety disorders refer to agoraphobia, generalized anxiety disorder, panic, and social and specific phobias; mood disorders refer to bipolar, dysthymia, and major depressive disorder; personality disorders refer to antisocial, borderline, and schizotypal personality disorders; eating disorders refer to anorexia nervosa, binge-eating disorder, and bulimia nervosa. Unweighted results are in italics. Source: National Epidemiologic Survey on Alcohol and Related Conditions III. ***p < .001.
coingest other substances at the same time when they use prescription drugs (Barrett, Darredeau, & Pihl, 2006; Garnier et al., 2009; McCabe et al., 2006 McCabe et al., , 2015 . There is a need to distinguish between simultaneous and concurrent polysubstance use behaviors among individuals with multiple SUDs because the longitudinal trajectories and related adverse substance-related consequences may differ between these two types of polysubstance use behaviors (Abé et al., 2013; Garnier et al., 2009; McCabe et al., 2006; SAMHSA, 2014b) .
We found that multiple SUDs were more prevalent among adults with other DSM-5 psychiatric disorders, especially mood, personality, and posttraumatic stress disorders. Notably, adults with multiple lifetime psychiatric disorders had more than 9 times greater odds of having past-year multiple SUDs relative to those with no lifetime psychiatric disorders, which is consistent with earlier work suggesting a small subset of U.S. adults with extremely high rates of psychiatric comorbidity based on previous versions of the DSM (Kessler et al., 2005) . Previous studies have found high rates of psychiatric comorbidity associated with nonalcohol drug use disorders, including other SUDs (Blanco et al., 2013; Compton et al., 2007 Compton et al., , 2013 Fenton et al., 2012; Hasin et al., 2016; McCabe et al., 2008) . At least one national study found that psychiatric comorbidity was greater among U.S.
adults with a nonalcohol drug use disorder who had sought substance abuse treatment or help seeking as compared to others in the general population with a drug use disorder (Compton et al., 2007) . A more recent study found that majority of individuals with multiple past-year SUDs had a lifetime personality disorder and did not utilize substance abuse treatment or other help seeking . Future work is needed to examine the associations between DSM-5 tobacco use disorders and other DSM-5 SUDs.
This study and the NESARC-III had several strengths and limitations that should be taken into account while considering implications of these findings. The NESARC-III represents the first nationally representative study to assess substance-specific SUDs and other psychiatric comorbidity based on DSM-5 criteria. The limitations of the NESARC-III included the cross-sectional design of the study, which prevents assessment and testing of causal relationships.
The response rate was lower than previous administrations of the NESARC (Grant & Kaplan, 2005; Grant, Kaplan, Shepard, & Moore, 2003) , and despite the fact that nonresponse adjustments were applied to the base sampling weights (Grant, Chu, Sigman, et al., 2015) , the higher rate of nonresponse may have biased survey estimates. Although more research is needed to determine the characteristics of nonrespondents in national substance use studies such as the NESARC-III, recent studies have found that attrition was higher among individuals with no SUDs in prior longitudinal versions of the NESARC (Dawson, Goldstein, Pickering, & Grant, 2014; McCabe & West, 2016) . In addition, the NESARC-III was interviewer administered, so caution should be exercised when comparing results from these studies and other sources of data based on different modes of data collection; the survey methodology literature suggests that our estimates may be biased low, given the ability of self-administered modes to generate more frequent reports of sensitive behaviors such as drug use (Turner, 2005) . Furthermore, the AUDADIS-5/PRISM-5 concordance was fair on some binary SUD diagnoses (e.g., past-year opioids). Finally, the exclusion of some institutionalized subpopulations with higher rates of SUDs, including inmate populations currently in jails and prisons, may have led to underestimation of SUD prevalence in the NESARC-III (Compton, Dawson, Duffy, & Grant, 2010) .
The majority of U.S. adults with a DSM-5 SUD involving cannabis, cocaine, heroin, hallucinogens, inhalants, prescription opioids, seda- 
